DE69232516T2 - Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung - Google Patents
Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende VerbindungInfo
- Publication number
- DE69232516T2 DE69232516T2 DE69232516T DE69232516T DE69232516T2 DE 69232516 T2 DE69232516 T2 DE 69232516T2 DE 69232516 T DE69232516 T DE 69232516T DE 69232516 T DE69232516 T DE 69232516T DE 69232516 T2 DE69232516 T2 DE 69232516T2
- Authority
- DE
- Germany
- Prior art keywords
- interleukin
- treatment
- pct
- inhibitory compound
- neurological conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919123161A GB9123161D0 (en) | 1991-10-31 | 1991-10-31 | Treatment of neurological conditions |
GB919125670A GB9125670D0 (en) | 1991-11-30 | 1991-11-30 | Treatment of neurogical conditions |
PCT/GB1992/002023 WO1993008820A1 (en) | 1991-10-31 | 1992-11-02 | Treatment of neurological conditions by an interleukin-1 inhibiting compound |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69232516D1 DE69232516D1 (de) | 2002-05-02 |
DE69232516T2 true DE69232516T2 (de) | 2002-10-31 |
Family
ID=26299779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69232516T Expired - Lifetime DE69232516T2 (de) | 1991-10-31 | 1992-11-02 | Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung |
Country Status (10)
Country | Link |
---|---|
US (1) | US6090775A (de) |
EP (1) | EP0610336B1 (de) |
JP (1) | JP3623501B2 (de) |
AT (1) | ATE214939T1 (de) |
AU (3) | AU2804192A (de) |
CA (1) | CA2122596C (de) |
DE (1) | DE69232516T2 (de) |
DK (1) | DK0610336T3 (de) |
ES (1) | ES2173871T3 (de) |
WO (2) | WO1993008820A1 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
US6159460A (en) * | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
US5843969A (en) * | 1995-04-07 | 1998-12-01 | Teijin Limited | Protecting agent for organ or tissue |
US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
US20030040660A1 (en) * | 2001-08-27 | 2003-02-27 | George Jackowski | Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein |
AU2002332931A1 (en) * | 2001-09-06 | 2003-03-24 | Board Of Regents, The University Of Texas System | Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor |
CA2588892A1 (en) * | 2004-12-02 | 2006-06-08 | Dormantis Limited | Anti-il-1r1 single domain antibodies and therapeutic uses |
EP1957537A2 (de) * | 2005-12-01 | 2008-08-20 | Domantis Limited | Kompetitive domänenantikörperformate, die an den interleukin-1-rezeptor vom typ 1 binden |
CA2749537C (en) * | 2009-01-09 | 2018-11-20 | The Schepens Eye Research Institute, Inc. | Il-1 antagonist compositions for corneal nerve regeneration and protection |
AU2011283669A1 (en) | 2010-07-29 | 2013-02-07 | Eleven Biotherapeutics, Inc. | Chimeric IL-1 receptor type I agonists and antagonists |
PL2968468T3 (pl) | 2013-03-13 | 2021-12-20 | Buzzard Pharmaceuticals AB | Preparaty chimerycznej cytokiny do dostarczania do oka |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL100533A (en) * | 1986-12-31 | 1994-05-30 | Hoechst Roussel Pharma | Pharmaceutical preparations containing a history of xanthine for VIH treatment and disease states |
US4965271A (en) * | 1986-12-31 | 1990-10-23 | Hoechst Roussel Pharmaceuticals, Inc. | Method of inhibiting the activity of leukocyte derived cytokines |
HU203198B (en) * | 1987-10-26 | 1991-06-28 | Sandoz Ag | Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect |
KR920702606A (ko) * | 1989-06-13 | 1992-10-06 | 스튜어트 알. 슈터 | 모노킨(Monokine)의 활성저해 |
AU649245B2 (en) * | 1990-04-02 | 1994-05-19 | Amgen, Inc. | Methods for treating interleukin-1 mediated diseases |
-
1992
- 1992-11-02 DK DK92922537T patent/DK0610336T3/da active
- 1992-11-02 JP JP50826093A patent/JP3623501B2/ja not_active Expired - Lifetime
- 1992-11-02 US US08/232,167 patent/US6090775A/en not_active Expired - Lifetime
- 1992-11-02 AT AT92922537T patent/ATE214939T1/de not_active IP Right Cessation
- 1992-11-02 CA CA002122596A patent/CA2122596C/en not_active Expired - Lifetime
- 1992-11-02 EP EP92922537A patent/EP0610336B1/de not_active Expired - Lifetime
- 1992-11-02 AU AU28041/92A patent/AU2804192A/en not_active Abandoned
- 1992-11-02 AU AU28845/92A patent/AU2884592A/en not_active Abandoned
- 1992-11-02 WO PCT/GB1992/002023 patent/WO1993008820A1/en active IP Right Grant
- 1992-11-02 ES ES92922537T patent/ES2173871T3/es not_active Expired - Lifetime
- 1992-11-02 WO PCT/GB1992/002019 patent/WO1993008819A1/en active Application Filing
- 1992-11-02 DE DE69232516T patent/DE69232516T2/de not_active Expired - Lifetime
-
1996
- 1996-12-24 AU AU76482/96A patent/AU7648296A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2122596C (en) | 2008-06-03 |
AU2884592A (en) | 1993-06-07 |
JP3623501B2 (ja) | 2005-02-23 |
EP0610336A1 (de) | 1994-08-17 |
CA2122596A1 (en) | 1993-05-13 |
ATE214939T1 (de) | 2002-04-15 |
JPH07505608A (ja) | 1995-06-22 |
AU2804192A (en) | 1993-06-07 |
DK0610336T3 (da) | 2002-07-22 |
AU7648296A (en) | 1997-02-13 |
WO1993008820A1 (en) | 1993-05-13 |
US6090775A (en) | 2000-07-18 |
EP0610336B1 (de) | 2002-03-27 |
DE69232516D1 (de) | 2002-05-02 |
WO1993008819A1 (en) | 1993-05-13 |
ES2173871T3 (es) | 2002-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT750618E (pt) | Derivados de oxazolidinona e composicoes farmaceuticas que os contem | |
ATE387215T1 (de) | Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff | |
ES2108120T3 (es) | Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf. | |
DE59400489D1 (de) | Fungizide Wirkstoffkombinationen | |
DE69232516T2 (de) | Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung | |
DE69200675D1 (de) | Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen. | |
ATE163418T1 (de) | Risperidon pamoate | |
ATE136026T1 (de) | Substituierte bizyklische arylderivate mit selektiver leukotrien b4 antagonistischer wirkung | |
DK1032556T3 (da) | Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder | |
ITMI920955A1 (it) | Idrogeli di tipo polietereammidoamminico come materiali eparinizzabili | |
ATE185071T1 (de) | Steroide enthaltende zusammensetzungen zur anwendung am auge und ihre verwendung zur behandlung des glaukoms | |
PT651648E (pt) | Composicoes farmaceuticas compreendendo il-6 e seu uso para o tratamento da doenca trombo-hemorragica destrutiva | |
DE59303446D1 (de) | Neue bis-phenyl-hexene | |
ES2144452T3 (es) | Medicamento para el tratamiento de infecciones protozoarias provocadas por babesia. | |
DK0722325T3 (da) | Præparat til behandling eller forebyggelse af herpes | |
BR0206262A (pt) | Composição antimicrobiana lìquida, uso da mesma, e, método de exterminar ou eliminar vìrus ou esporos | |
NO921525L (no) | L-alfa-glyserofosforyl-d-myo-inositol for behandling av perifere nervelidelser og hjernelidelser | |
KR950016739A (ko) | 강박관념 질환 및 소모성 질환을 억제하는 방법 | |
ATE333287T1 (de) | Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten | |
ES2098119T3 (es) | Nuevas triazoloquinazolinas, su obtencion y empleo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: THE UNIVERSITY OF MANCHESTER, MANCHESTER, GB |
|
8328 | Change in the person/name/address of the agent |
Representative=s name: PATENTANWAELTE ZELLENTIN & PARTNER GBR, 81667 MUENCHEN |
|
R071 | Expiry of right |
Ref document number: 610336 Country of ref document: EP |